Practices

Life Sciences IP Litigation

We combine deep technical knowledge with best-in-class trial advocacy to protect and enforce our clients’ intellectual property

Why Cooley

  • Decades of experience resolving high-stakes disputes in the life sciences space across key jurisdictions, including Hatch-Waxman matters for branded pharmaceutical companies and complete wins in commercially significant drug ownership and licensing disputes

  • Integrated within Cooley’s renowned life sciences practice, we have significant experience in related areas, such as antitrust laws and US Food and Drug Administration (FDA) and regulatory issues, and we collaborate seamlessly with our robust patent prosecution team

  • Multidisciplinary team of industry-leading IP lawyers, including 100+ IP professionals with doctorate and master’s degrees across science and engineering disciplines

  • Unique ability to break down complex scientific subject matter to educate and persuade judges and jurors

  • Strategic pre-litigation counsel in anticipation of product launches within the context of regulatory schemes

  • More than 400 inter partes review (IPR) proceedings to date with a 70%+ institution success rate, and leading experience on both sides of US Patent Trial and Appeal Board (PTAB) proceedings

Read more

Recognition

  • Chambers USA: Intellectual Property – Nationwide (2025)
  • Chambers USA: Life Sciences: IP/Patent Litigation – California (2025)
  • The Legal 500 US: Patents: litigation (full coverage) (2025) 
  • LMG Life Sciences: General Patent Litigation Firm of the Year, finalist (2024)
  • LMG Life Sciences: Hatch-Waxman Litigation Firm of the Year – Branded (2024)
  • The American Lawyer: IP Litigation Department of the Year finalist (2023, 2025)
  • LMG Life Sciences: Patent Strategy and Management Firm of the Year, honoree (2023)
  • Managing Intellectual Property: Patent Contentious, PTAB Litigation and Life Sciences “IP Star” (2023)

The Cooley team is nimble, pragmatic and has a finger on the pulse of the market.

Chambers USA, 2025

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as "Cooley"). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction, and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. When advising companies, our attorney-client relationship is with the company, not with any individual. This content may have been generated with the assistance of artificial intelligence (Al) in accordance with our Al Principles, may be considered Attorney Advertising and is subject to our legal notices.